Role of Diphosphonates Bone Scintigraphy in Correlation with Biomarkers for a Personalized Approach to ATTR Cardiac Amyloidosis in North-Eastern Romania.
ATTR
biomarkers
bone scintigraphy
Journal
Diagnostics (Basel, Switzerland)
ISSN: 2075-4418
Titre abrégé: Diagnostics (Basel)
Pays: Switzerland
ID NLM: 101658402
Informations de publication
Date de publication:
28 Dec 2022
28 Dec 2022
Historique:
received:
31
10
2022
revised:
13
12
2022
accepted:
23
12
2022
entrez:
8
1
2023
pubmed:
9
1
2023
medline:
9
1
2023
Statut:
epublish
Résumé
Transthyretin cardiac amyloidosis (ATTR) is a rare cardiac protein deposition disease characterized by progressive thickening of both ventricles, the inter-atrial-ventricular septum and the atrioventricular valves. The gold standard method for diagnosing this rare pathology is endomyocardial biopsy. If this method cannot be used, the alternative is a mixture of clinical and paraclinical tests. Over the course of five years, we examined 58 patients suspected of cardiac amyloidosis based on electrocardiography and ultrasonography criteria, who had been sent for bone scintigraphy in order to determine the presence of ATTR cardiac amyloidosis. However, the final diagnosis was set by correlating the bone scan with genetic testing, free light chain dosage or soft tissue biopsy. Based on the final diagnosis we analyzed the patients' predominant biomarkers in order to determine a possible correlation between them. This analysis is designed to help the general practitioner set a possible cardiac amyloidosis diagnosis.
Identifiants
pubmed: 36611375
pii: diagnostics13010083
doi: 10.3390/diagnostics13010083
pmc: PMC9818064
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Annu Rev Med. 2020 Jan 27;71:203-219
pubmed: 31986086
J Nucl Cardiol. 2020 Apr;27(2):659-673
pubmed: 31468377
J Nucl Cardiol. 2019 Feb;26(1):158-173
pubmed: 30569412
JACC Heart Fail. 2019 Aug;7(8):709-716
pubmed: 31302046
Rev Esp Cardiol (Engl Ed). 2017 Nov;70(11):991-1004
pubmed: 28870641
Can J Cardiol. 2020 Mar;36(3):424-431
pubmed: 32145869
Amyloid. 2014 Mar;21(1):35-44
pubmed: 24455993
Diagnostics (Basel). 2022 Mar 03;12(3):
pubmed: 35328180
Int J Cardiol Heart Vasc. 2020 Apr 27;28:100519
pubmed: 32373710
JACC Cardiovasc Imaging. 2021 May;14(5):1072-1074
pubmed: 33221227
Am J Med. 2022 Apr;135 Suppl 1:S2-S8
pubmed: 35081377
J Nucl Cardiol. 2021 Dec;28(6):2845-2856
pubmed: 32385832
Curr Probl Cardiol. 2018 Jan;43(1):10-34
pubmed: 29173805
Hellenic J Cardiol. 2020 Mar - Apr;61(2):92-98
pubmed: 31740363
Diagnostics (Basel). 2021 May 06;11(5):
pubmed: 34066384
Nucl Med Commun. 2022 Nov 1;43(11):1109-1112
pubmed: 36164705
J Nucl Cardiol. 2018 Oct;25(5):1879-1884
pubmed: 29188431
Amyloid. 2019 Sep;26(3):118-124
pubmed: 31122115
Heart Fail Rev. 2021 Jul;26(4):861-879
pubmed: 33452596
J Card Fail. 2019 Nov;25(11):e1-e39
pubmed: 31473268
Eur Heart J. 2021 Sep 21;42(36):3599-3726
pubmed: 34447992
Curr Cardiol Rep. 2019 Aug 2;21(9):108
pubmed: 31375984
Neth Heart J. 2019 Nov;27(11):525-536
pubmed: 31359320
Eur Heart J Suppl. 2020 Jun;22(Suppl E):E142-E147
pubmed: 32523459
Eur Heart J. 2021 Apr 21;42(16):1554-1568
pubmed: 33825853
Eur Heart J Cardiovasc Imaging. 2017 Dec 01;18(12):1344-1350
pubmed: 28159995
Rev Assoc Med Bras (1992). 2020 Mar;66(3):345-352
pubmed: 32520156
J Nucl Cardiol. 2018 Feb;25(1):217-222
pubmed: 27804073
Cleve Clin J Med. 2017 Dec;84(12 Suppl 3):12-26
pubmed: 29257735
Trends Cardiovasc Med. 2018 Jan;28(1):10-21
pubmed: 28739313
Eur Heart J Case Rep. 2020 Nov 06;4(6):1-6
pubmed: 33629008
Eur Heart J. 2018 Aug 7;39(30):2799-2806
pubmed: 29048471
Medicine (Baltimore). 2019 Sep;98(38):e17256
pubmed: 31567998
J Am Coll Cardiol. 2005 Sep 20;46(6):1076-84
pubmed: 16168294